The research team, led by Xiaoyu Yang and Xiaoning Jiang with corresponding author Fan Wang, drew on trials conducted in patients aged 60 and older undergoing major orthopedic procedures such as hip and knee surgery. These operations are among the most common reasons older adults end up in the operating room, and they carry a substantial risk of delirium. The condition is not a minor side effect. Postoperative delirium is associated with longer hospital stays, increased rates of institutional discharge, accelerated cognitive decline, and higher mortality. For decades, clinicians have relied mainly on non-drug prevention strategies, such as reorientation protocols, sleep hygiene, early mobilization, and vision and hearing aids, because no pharmacological approach had been clearly validated.

The appeal of drug-based prevention lies in the biology of delirium itself. Scientists believe that surgical trauma triggers a cascade of neuroinflammatory events. Tissue injury releases damage-associated molecular patterns, which activate immune signaling and can drive elevations in inflammatory molecules such as interleukin-6 and tumor necrosis factor-alpha. These signals can disrupt the blood-brain barrier and disturb neurotransmitter systems, particularly acetylcholine and the N-methyl-D-aspartate receptor pathways, tipping the aging brain into the acute disorganization that defines delirium. The drugs tested in the trials reviewed here were chosen precisely because they interact with these pathways, either by damping inflammation or by protecting neurons from stress-related injury.

To compare these strategies fairly, the researchers performed a network meta-analysis, a statistical technique that allows both direct comparisons, from trials that tested two treatments against each other, and indirect comparisons, inferred through shared comparators such as placebo. They systematically searched four electronic databases for randomized controlled trials evaluating perioperative pharmacological strategies for postoperative delirium or postoperative cognitive outcomes in older orthopedic patients. Crucially, for the primary quantitative analysis, delirium had to be diagnosed using a validated instrument, such as the Confusion Assessment Method or the 3-Minute Diagnostic Confusion Assessment Method, rather than by informal clinical impression. This requirement matters because delirium is notoriously under-recognized at the bedside, and screening tools dramatically change detection rates.

Eighteen randomized controlled trials encompassing 4,132 participants made it into the systematic review. Of these, thirteen trials involving 3,466 participants formed the primary network for the delirium analysis, containing nine distinct treatment nodes. The team used a frequentist random-effects model and, importantly, modeled active drug comparisons separately from inert placebo or standard-care controls, a methodological choice designed to avoid distorting effect estimates. They reported odds ratios with 95 percent confidence intervals, which describe the precision of the observed effect, and also 95 percent prediction intervals, which estimate the range of effects one might expect in a future, real-world setting. They ranked treatments using P-scores, built a league table of all pairwise comparisons, mapped how much each trial contributed to the network, and graded the certainty of the evidence using a GRADE and CINeMA-style framework.

The headline findings were striking. Four interventions produced odds ratios whose confidence and prediction intervals both excluded the value of one, the threshold of no effect. An anti-inflammatory bundle showed the largest estimated benefit, with an odds ratio of 0.21, meaning roughly a 79 percent reduction in the odds of delirium compared with control. Dexmedetomidine produced an odds ratio of 0.37, dexamethasone 0.36, and parecoxib 0.46. Among these, dexmedetomidine stood out for a different reason: it was supported by the largest evidence base in the network, making its estimate the most trustworthy of the group. Dexmedetomidine is an alpha-2 adrenergic agonist, a sedative that calms patients without suppressing respiration, and it is already widely used in intensive care and anesthesia settings, which makes a preventive role particularly practical.

Not every candidate drug fared as well. Esketamine, an anesthetic agent acting on the NMDA receptor that had attracted interest for its neuroprotective potential, did not show a statistically significant protective effect against placebo, with an odds ratio of 0.77 and a confidence interval spanning 0.33 to 1.76. The researchers also tested whether the type of surgery modified how well the drugs worked, comparing effects across different orthopedic contexts. It did not. Interaction tests for dexmedetomidine, parecoxib, and propofol all returned non-significant p-values of 0.26, 0.50, and 0.53 respectively, meaning the analysis demonstrated no surgical-stress-dependent treatment hierarchy. In other words, there was no evidence that a particular operation type made one drug strategy clearly superior to another.

The authors were careful to temper enthusiasm with appropriate scientific caution. Certainty of the evidence remains moderate at best, and the network is sparse, with no independent closed loops, meaning the indirect estimates rest on relatively thin connections between trials. Several of the promising effect estimates, including the eye-catching figure for the anti-inflammatory bundle, rest on single small trials that could overstate true benefit. This is a well-known phenomenon in meta-analysis, where early small studies often report larger effects than later, better-powered replications. The prediction intervals, which account for between-study heterogeneity, help guard against false confidence, and the fact that four interventions passed that stricter test is genuinely encouraging, but the authors concluded that adequately powered, standardized head-to-head randomized trials are still needed before any drug can be recommended for routine prophylaxis.

Even so, the implications for perioperative medicine are significant. Hip fracture repair and joint replacement are performed millions of times each year worldwide, and the population undergoing them continues to age. If a low-cost, well-characterized drug such as dexmedetomidine, delivered during and around surgery, can meaningfully cut delirium risk, the potential public health impact is enormous, spanning shorter hospitalizations, fewer nursing home admissions, and preserved cognition for vulnerable patients. The study also delivers a methodological message to the field: future trials should use validated delirium screening instruments, consistent dosing protocols, and direct comparisons between the leading candidates rather than yet another placebo-controlled test of a single agent. Until those head-to-head studies arrive, this analysis provides the clearest map yet of which pharmacological strategies deserve the spotlight, and it places a familiar sedative at the center of one of geriatric surgery’s most urgent unanswered questions.

Subject of Research: Pharmacological prevention of postoperative delirium in older adults undergoing major orthopedic surgery

Article Title: Perioperative pharmacological prophylaxis of postoperative delirium after major orthopedic surgery in older adults: a systematic review and network meta-analysis of randomized controlled trials

Article References: Yang, X., Jiang, X., Xiao, R., Liu, J., Guo, Y., Ji, Y., Zhao, F., & Wang, F. (2026). Perioperative pharmacological prophylaxis of postoperative delirium after major orthopedic surgery in older adults: a systematic review and network meta-analysis of randomized controlled trials. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08430-6

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08430-6

Keywords: postoperative delirium, dexmedetomidine, orthopedic surgery, network meta-analysis, older adults, geriatrics, anesthesia, neuroinflammation, randomized controlled trials, dexamethasone, parecoxib, perioperative medicine

The review, authored by Hou-Ming Kan of Macau University of Science and Technology, Hong-Yan Ni of Suqian First Hospital, and colleagues across institutions in China, surveys a rapidly expanding toolkit of non-invasive neuromodulation techniques and evaluates their promise against one of medicine’s most underappreciated complications. The authors systematically examine nine distinct approaches: transcranial direct current stimulation, repetitive transcranial magnetic stimulation, theta burst stimulation, transcranial alternating current stimulation, transcranial ultrasound stimulation, temporal interference stimulation, transcutaneous auricular vagus nerve stimulation, transcranial photobiomodulation, and 40-hertz gamma entrainment using sensory stimuli. Each technique manipulates neural activity from outside the skull, and each, according to the accumulating evidence reviewed by the team, may offer a route to protecting the aging brain from the assault of anesthesia and surgery.

The appeal of these technologies lies in their physical diversity. Transcranial direct current stimulation passes a weak, constant electrical current through electrodes on the scalp, subtly shifting the excitability of cortical neurons beneath them. Repetitive transcranial magnetic stimulation, by contrast, uses rapidly alternating magnetic fields to induce electrical currents inside the brain, and its condensed cousin, theta burst stimulation, delivers the same influence in bursts that mimic the brain’s natural theta rhythm, cutting session times from nearly an hour to just minutes. Transcranial alternating current stimulation goes further, entraining neural oscillations at specific frequencies, while transcranial ultrasound stimulation uses focused sound waves to excite or suppress neurons with millimeter-scale precision. Temporal interference stimulation represents perhaps the most elegant trick of all: two high-frequency currents that are harmless on their own are steered so that they cross deep inside the brain, where their interference produces a low-frequency beat capable of stimulating structures that scalp electrodes can never reach.

Two of the most intriguing techniques bypass the skull entirely. Transcutaneous auricular vagus nerve stimulation delivers gentle electrical pulses to the ear, activating the vagus nerve’s auricular branch and, through its connections to the nucleus tractus solitarius and the dorsal raphe nucleus, modulating widespread networks that govern inflammation, arousal, and mood. Transcranial photobiomodulation takes an entirely different route, shining near-infrared light through the scalp and skull to be absorbed by cytochrome c oxidase in neuronal mitochondria, boosting adenosine triphosphate production and triggering downstream effects on blood flow, neurotrophic factors, and antioxidant defenses. And in a nod to research that has captivated the Alzheimer’s field, the review also covers gamma entrainment using sensory stimuli, in which flickering lights or clicking sounds tuned to 40 hertz coax the brain’s gamma oscillations back into sync, a rhythm that grows feeble in dementia and delirium alike.

Why would any of this matter for a patient undergoing a hip replacement or cardiac surgery? The review lays out the biology of perioperative neurocognitive disorders in sobering detail. Anesthesia and the surgical stress response trigger a cascade of peripheral inflammation, and inflammatory signals breach the weakened blood-brain barrier, activating microglia and astrocytes. The complement cascade, the NLRP3 inflammasome, and markers such as high-mobility group box 1 and lipocalin 2 all feature in the preclinical literature as drivers of neuronal injury. Cholinergic deficits, oxidative stress marked by molecules like 4-hydroxynonenal and malondialdehyde, disrupted calcium handling through the SERCA pump, and impaired clearance of waste through the aquaporin-4-dependent glymphatic system complete a picture of a brain under siege. Crucially, many of these mechanisms are precisely the targets that neuromodulation can reach: vagus nerve stimulation dampens systemic inflammation, photobiomodulation restores mitochondrial energy metabolism, and gamma entrainment appears to enhance microglial clearance of amyloid and improve synaptic integrity in animal models.

The preclinical evidence reviewed by the authors is encouraging. In rodent models of surgery-induced cognitive impairment, transcranial direct current stimulation and near-infrared light have been shown to preserve long-term potentiation, the cellular substrate of memory, while reducing inflammatory cytokines such as interleukin-1 beta and interleukin-6 in the hippocampus. Photobiomodulation studies report increased expression of brain-derived neurotrophic factor, protection of myelin basic protein, and even promotion of oligodendrocyte precursor cell maturation, suggesting the technique may help repair white matter damaged by the perioperative insult. Vagus nerve stimulation in animal models reduces neuroinflammation through the cholinergic anti-inflammatory pathway, engaging alpha-7 nicotinic acetylcholine receptors on immune cells. Even gut-directed photobiomodulation has entered the picture, with the review noting emerging work on gut microbiota-targeted approaches that modulate the microbiome-gut-brain axis through short-chain fatty acids.

Translating these findings to the clinic, however, is where the story becomes both promising and cautionary. The review compiles preliminary clinical trials in which non-invasive neuromodulation was applied to surgical patients, including studies using transcranial direct current stimulation and transcutaneous auricular vagus nerve stimulation in populations at high risk for postoperative delirium, such as elderly patients undergoing total joint arthroplasty. The early signals suggest reductions in delirium incidence and improvements in cognitive screening scores measured with instruments like the Mini-Mental State Examination and the Montreal Cognitive Assessment, alongside objective monitoring using electroencephalography and functional near-infrared spectroscopy. Yet the authors are explicit that the evidence base remains immature: sample sizes are small, stimulation protocols vary widely between studies, and few trials have been designed with the methodological rigor of large, multicenter randomized controlled trials.

The technical challenges are considerable. The review emphasizes that parameters matter enormously: current intensity, electrode montage, session duration, timing relative to surgery, and frequency selection can each determine whether a protocol helps, does nothing, or theoretically causes harm. The dorsolateral prefrontal cortex, a hub of executive control that frequently falters in delirium, has been the favored target for most stimulation protocols, but the authors argue that future work must move beyond single regions and consider the brain as a network. They call for multimodal monitoring that combines electroencephalography, functional magnetic resonance imaging of the default mode network, and near-infrared spectroscopy to track how stimulation reshapes global connectivity, rather than merely measuring whether a patient passes a bedside confusion assessment. The posterior cingulate cortex, the hippocampal dentate gyrus, and even the nucleus accumbens all appear in the review as nodes whose dysfunction may contribute to the delirium phenotype.

What emerges from this comprehensive synthesis is a field standing at an inflection point. The convergence of an aging surgical population, a complete absence of pharmacological options, and a maturing neuromodulation industry creates a rare window for translational progress. The authors, whose work was supported by the Suqian Sci&Tech Program and the China Postdoctoral Science Foundation, lay out a roadmap that reads like a checklist for the coming decade: strict randomized clinical trials, standardized stimulation protocols, optimization of device parameters, and adoption of network-level brain monitoring. If those steps succeed, the prospect of a patient slipping on a lightweight stimulation cap before surgery, or listening to 40-hertz tones in the recovery room, could shift from science fiction to standard of care. For the millions of patients and families who dread the fog that can follow anesthesia, the idea that the brain might be shielded by nothing more than carefully patterned electricity, magnetism, light, and sound is a vision worth watching closely, and one that the next generation of clinical trials will soon put to the test.

Subject of Research: Non-invasive neuromodulation for preventing perioperative neurocognitive disorders and postoperative delirium

Article Title: Perioperative non-invasive neuromodulation for delirium and cognitive recovery: from preclinical evidence to clinical translation

Article References: Perioperative non-invasive neuromodulation for delirium and cognitive recovery: from preclinical evidence to clinical translation. (n.d.). https://doi.org/10.1186/s12967-026-08979-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08979-1

Keywords: perioperative neurocognitive disorders, postoperative delirium, postoperative cognitive dysfunction, non-invasive neuromodulation, transcranial direct current stimulation, transcranial magnetic stimulation, vagus nerve stimulation, photobiomodulation, gamma entrainment, anesthesia, neuroinflammation, brain stimulation

The research team, led by investigators at Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School, took an unusually comprehensive approach, weaving together human proteomics, a prospective surgical cohort, and mechanistic experiments in mice and cultured neurons. Their starting point was the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large longitudinal study in which cerebrospinal fluid from thousands of participants has been profiled using the SomaScan 7K platform, an aptamer-based technology capable of measuring more than 7,000 molecular analytes simultaneously. From this resource, the researchers defined an exploratory phenotype they call neurodegeneration-enriched cognitive vulnerability, or NECV: individuals with mild cognitive impairment who also had a documented history of surgery. By comparing the proteomic fingerprints of 152 NECV participants against 85 cognitively normal controls, and applying stringent Bonferroni correction across more than 6,000 unique proteins, they found that 14-3-3γ ranked among the top candidates, occupying a central position in the co-expression network of disease-relevant proteins.

The signal held up under scrutiny. Cerebrospinal fluid levels of 14-3-3γ were dramatically elevated in the NECV group compared with controls, a difference that reached an extraordinary statistical significance of p = 7.8 × 10⁻³². The finding replicated independently in the Parkinson’s Progression Markers Initiative (PPMI) cohort and was further confirmed in autopsy-verified Alzheimer’s disease samples. Crucially, the protein was not merely a static marker. In longitudinal survival analyses, participants with higher baseline CSF 14-3-3γ faced an increased hazard of progressing from normal cognition to prodromal Alzheimer’s disease, and those already in the vulnerable group progressed more rapidly to frank dementia. Elevated 14-3-3γ also tracked with the classic molecular hallmarks of neurodegeneration: lower CSF amyloid-beta 42, higher phosphorylated and total tau, greater cortical amyloid burden on PET imaging, smaller hippocampal volumes, reduced cerebral glucose metabolism, and steeper declines in memory, executive function, and global cognition over time.

What elevates this work beyond biomarker correlation is its translation into the surgical setting. The team prospectively enrolled 213 patients aged 65 and older undergoing major elective cardiac, orthopedic, or aortic surgery at their tertiary center, a study registered with the Chinese Clinical Trial Registry. Blood drawn on the first postoperative day, before any delirium had been documented, revealed that patients who subsequently developed postoperative delirium or POCD had significantly higher circulating 14-3-3γ levels than those who recovered uneventfully. In this cohort, 22 patients (10.3 percent) developed delirium within the first week, while 11 (5.2 percent) met criteria for POCD at day seven, all consistent with delayed neurocognitive recovery under the 2018 nomenclature consensus. When plasma 14-3-3γ was added to models built from routine clinical variables, predictive performance improved substantially: the area under the receiver operating characteristic curve for delirium rose from 0.819 to 0.921, and for POCD from 0.705 to 0.864, with statistically significant gains confirmed by DeLong tests. Decision curve and precision-recall analyses suggested the combined models offered genuine net clinical benefit, though the authors are careful to frame these findings as exploratory given the modest number of outcome events.

One of the most intriguing puzzles the study surfaces is a striking compartmental divergence. After surgery, 14-3-3γ levels fell markedly inside hippocampal neurons in mice, yet rose in the blood and cerebrospinal fluid of both mice and humans. The researchers propose that the extracellular elevation reflects a spillover phenomenon, a leakage of intracellular proteins from injured neurons, a pattern long recognized in conditions such as Creutzfeldt-Jakob disease, stroke, and traumatic brain injury, where CSF 14-3-3 proteins serve as markers of neuronal damage. The intracellular depletion, by contrast, may be the pathologically decisive event. The 14-3-3 family constitutes roughly one percent of total soluble brain protein, and its loss would destabilize a web of protein-protein interactions governing tau phosphorylation, mitochondrial function, and synaptic maintenance. In other words, the protein leaking into the bloodstream may be a useful warning signal, but the deficit left behind inside vulnerable neurons is what drives the damage.

To establish causality, the team turned to a murine model of perioperative brain injury in which mice undergo tibial fracture with intramedullary fixation under isoflurane anesthesia, a procedure that recapitulates key clinical features of major orthopedic surgery, including tissue trauma, inflammation, and postoperative pain. Within days, surgically treated mice showed impaired performance in the Y-maze spontaneous alternation test and contextual fear conditioning, both hippocampus-dependent tasks, while locomotor activity and cued memory remained intact, pointing to a specific rather than global deficit. Electron microscopy revealed fragmented microtubules, the intracellular highways that tau normally stabilizes. Golgi staining showed a loss of mature dendritic spines, the tiny protrusions where synapses form. Levels of the synaptic proteins PSD95 and synaptophysin dropped, synaptic clefts widened, and postsynaptic densities thinned. Biochemically, the surgery produced a selective and sustained hyperphosphorylation of tau at the threonine 205 residue, detectable and pronounced at postoperative day seven, while other phosphorylation sites examined, including Thr231, Ser396, and Ser262, remained unchanged at that timepoint.

The mechanistic thread connecting 14-3-3γ loss to tau damage runs through the enzymes that control tau’s phosphorylation state. When the researchers silenced 14-3-3γ in HT22 hippocampal cells, they observed activation of CDK5, reflected in an increased p25-to-p35 ratio; activation of GSK3β, seen as reduced inhibitory phosphorylation at Ser9; and inhibition of the phosphatase PP2A, marked by increased phosphorylation at Tyr307. The net effect was a shift toward kinase-dominated regulation of tau, and tau Thr205 phosphorylation climbed accordingly. Pharmacologically damping CDK5 with roscovitine, blocking GSK3β with lithium chloride, or activating PP2A with DT061 each reversed the hyperphosphorylation. Co-immunoprecipitation experiments added a structural dimension: loss of 14-3-3γ reduced the association of phosphorylated tau with the protective phosphatase PP2A while increasing its association with the kinases CDK5 and GSK3β. Immunoprecipitation followed by mass spectrometry independently identified tau as a binding partner of 14-3-3γ, and the interaction proved sensitive to the Thr205 phosphorylation state, with a phospho-mimetic T205E tau mutant binding more strongly and a phospho-deficient T205A mutant binding more weakly.

The therapeutic implications emerged from two elegant intervention experiments. First, when the researchers delivered a gene therapy vector carrying 14-3-3γ directly into the hippocampal CA1 region and dentate gyrus of mice via adeno-associated virus, the overexpression suppressed surgery-induced tau Thr205 hyperphosphorylation, restored microtubule integrity and synaptic architecture, recovered dendritic spine density, and rescued working memory and contextual fear memory. Second, and perhaps most provocatively, the team tested fusicoccin-A, a small molecule known to stabilize 14-3-3 protein-protein interactions. Administered intraperitoneally before surgery, fusicoccin-A enhanced the binding between 14-3-3γ and phosphorylated tau, restored their colocalization in hippocampal neurons, rescued synaptic protein levels, reduced tau Thr205 phosphorylation without altering total tau, and improved cognitive performance in the Y-maze and fear conditioning tests. Molecular dynamics simulations running 500 nanoseconds per system showed that fusicoccin-A binding shortened the center-of-mass distance between the two proteins, reduced structural fluctuation, and rendered the binding free energy more favorable, providing a physical basis for the stabilization. Critically, when the researchers expressed a phosphomimetic TauT205E mutant in the hippocampus, the mutant alone was sufficient to impair cognition, and it abolished the protective effect of fusicoccin-A, demonstrating that tau Thr205 phosphorylation sits downstream in the protective pathway.

The authors are candid about the limitations that temper these exciting results. The ADNI-based discovery analysis is hypothesis-generating rather than direct evidence about POCD, since that cohort lacks detailed perioperative data. The prospective surgical cohort, though consecutively enrolled, produced few outcome events, limiting the robustness of the prediction models. The mouse experiments used young adult male animals rather than the aged populations most at risk clinically, and only a single small-molecule modulator was tested, leaving dose-response relationships, chronic effects, and safety profiles unexplored. Species differences in 14-3-3 regulation and tau dynamics may also affect translational relevance. Nevertheless, the study represents a genuine conceptual advance: it elevates 14-3-3γ from a passive correlate of neurodegeneration to an active, druggable regulator of acute cognitive vulnerability, and it points toward a strategy for protecting the surgical brain that is fundamentally different from conventional anti-amyloid or anti-tau therapies. If larger, multicenter trials confirm that a simple postoperative blood test for 14-3-3γ can flag patients at risk, and if stabilizers of the 14-3-3γ-tau interaction can be developed into safe drugs, the era of passively watching surgical patients lose their cognitive edge may finally give way to one of prediction and prevention.

Subject of Research: The role of 14-3-3γ in regulating tau Thr205 phosphorylation and synaptic integrity in postoperative cognitive dysfunction

Article Title: 14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

Article References: Zhu, S., Han, X., Zhang, H., Ye, C., Xia, T., & Gu, X. (2026). 14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity. Advanced Science, Article e77480. https://doi.org/10.1002/advs.77480

Image Credits: AI Generated

DOI: 10.1002/advs.77480

Keywords: postoperative cognitive dysfunction, 14-3-3γ, YWHAG, tau phosphorylation, Thr205, synaptic integrity, biomarker, postoperative delirium, fusicoccin-A, CSF proteomics, hippocampus, neurodegeneration

The study, published in European Geriatric Medicine by a team led by Marinus Fislage of Charité – University Medical Center Berlin, examined 618 patients aged 65 and older who were scheduled for elective surgery expected to last at least 60 minutes. None of the participants had dementia, and all had routinely obtained preoperative sodium measurements available. Using standard clinical thresholds, the researchers classified 31 patients, or 5.0 percent of the cohort, as hyponatremic, with sodium values ranging from 125 to 134 mmol/L, and 16 patients, or 2.6 percent, as hypernatremic, with values between 146 and 150 mmol/L. In total, only 7.5 percent of these older surgical patients carried any sodium abnormality before their operation, a figure that itself is informative about how uncommon clinically relevant dysnatremia is in an elective surgical population.

The raw numbers, however, were striking. Patients with abnormal sodium levels fared dramatically worse across every outcome the investigators tracked. Postoperative delirium, an acute and often devastating disturbance of attention and cognition that affects roughly one in five older surgical patients, occurred in 38.3 percent of the dysnatremia group compared with 20.8 percent of those with normal sodium. In-hospital mortality was more than tenfold higher, at 17.0 percent versus 1.6 percent. By 90 days after surgery, 27.7 percent of patients with abnormal sodium had died, compared with just 2.8 percent of the normonatremic group. Severe complications, graded as Clavien-Dindo class II or higher, affected 65.2 percent of the dysnatremia group against 38.4 percent of the rest. On the surface, these are the kinds of associations that make headlines and prompt calls for routine sodium-targeted interventions.

But the BioCog team asked a more demanding question than whether abnormal sodium and bad outcomes travel together. They wanted to know whether adding sodium to prediction models that already contain established clinical risk factors actually improves the models’ ability to distinguish which individual patients will suffer delirium, complications, or death. This distinction matters enormously in clinical practice. A variable can be strongly associated with an outcome in aggregate yet add almost nothing to individual-level prediction if its information is already captured by other variables, or if the abnormality is simply too rare to move the needle for the population as a whole. Confusing these two properties, association and incremental predictive value, is one of the most common pitfalls in biomarker research, and the study was explicitly designed to avoid it.

The methodological machinery the researchers deployed reflects that ambition. For each outcome, they built multivariable prediction models incorporating established clinical risk factors and then measured what happened when abnormal sodium was added. Discrimination, the model’s ability to separate patients who experience an outcome from those who do not, was quantified using the area under the receiver-operating characteristic curve, or AUROC, with bootstrap correction to guard against over-optimism. Calibration, whether predicted probabilities match observed event rates, was assessed with Brier scores, which penalize both discrimination failures and miscalibration. Postoperative delirium, the primary outcome, was assessed not by impression but with a battery of four validated diagnostic tests, a rigor that distinguishes BioCog from many chart-based delirium studies.

The verdict on delirium and complications was sobering. Adding dysnatremia to the delirium model nudged the AUROC from 0.71 to 0.72, but the bootstrap-corrected difference was a mere 0.0045, with a 95 percent confidence interval stretching from −0.0027 to 0.0199, a range that includes zero. For postoperative complications, the picture was nearly identical, with an optimism-corrected gain of 0.004 and a confidence interval of −0.0011 to 0.0124. Brier scores showed only marginal differences for these outcomes as well. In plain terms, knowing a patient’s sodium status before surgery tells a clinician almost nothing about that individual’s risk of delirium or complications beyond what age, comorbidity, type of surgery, and other established factors already reveal. The 38 percent delirium rate among dysnatremic patients is alarming, but with only 47 such patients in the cohort, the signal is too sparse and too entangled with other risk markers to sharpen anyone’s individual forecast.

Mortality told a subtler story. For in-hospital death, incorporating dysnatremia raised the optimism-corrected AUROC from 0.864 to 0.889, a difference of 0.023 with a confidence interval of 0.0046 to 0.0435 that excludes zero. For 90-day mortality, the bootstrap-validated C-index climbed from 0.91 to 0.93, a median increase of 0.021 with a confidence interval of 0.001 to 0.057. These are small but statistically reliable gains, and the authors are careful to frame them as exploratory findings that warrant further study rather than as a mandate for clinical change. Even here, the Brier scores barely moved, suggesting that while sodium helps rank patients by mortality risk, it does little to improve the accuracy of the predicted probabilities themselves. A gain of roughly two hundredths of a C-index, in the framework of decision-analytic literature on new markers, rarely justifies changes in care pathways on its own.

Why does a marker so visibly linked to death and delirium fail as a predictor? The answer lies in biology and in arithmetic. Dysnatremia in older adults is rarely an isolated electrolyte quirk; it is typically the downstream consequence of heart failure, kidney disease, malignancy, diuretic use, or general frailty, all of which are already captured by the covariates in a well-constructed prediction model. Sodium, in this sense, behaves as a messenger summarizing information the model already possesses. Meanwhile, its rarity, affecting fewer than one in twelve patients in this elective cohort, mathematically caps how much any population-level discrimination metric can improve. Prior large studies, including an analysis of major surgical populations by Cecconi and colleagues and a Danish cohort of nearly 280,000 acutely hospitalized patients, have consistently shown that even mild hyponatremia carries elevated mortality risk, yet the BioCog results suggest that in elective surgery the marker’s predictive ceiling is low precisely because the sickest patients are filtered out before they reach the operating room.

The clinical implications cut in two directions. On one hand, the study argues against investing heavily in sodium-based risk stratification tools for delirium prevention or complication prediction in older elective surgical patients; existing algorithms, including one recently developed and internally validated from the same BioCog cohort and published in the British Journal of Anaesthesia, already perform well without it. On the other hand, the strong associations with mortality serve as a reminder that a preoperative sodium value outside the 135 to 145 mmol/L range should never be dismissed as an incidental finding. It may not refine a risk calculator, but it flags a patient whose physiology is already compromised, prompting clinicians to consider whether the underlying cause, whether medication-related, endocrine, or organ-specific, can be identified and corrected before surgery. Trials of perioperative fluid management and prehabilitation programs, both active areas of research, may eventually determine whether intervening on modifiable contributors to dysnatremia can convert this marker of risk into a target of therapy.

For the growing field of perioperative medicine, the BioCog analysis offers a methodological template as much as a clinical message. By formally quantifying incremental predictive value with bootstrap-corrected discrimination metrics and Brier scores, rather than resting on relative risks alone, the researchers demonstrate how the surgical community should evaluate any candidate biomarker, from inflammatory panels to genetic signatures, before it earns a place in preoperative workflows. The study was conducted under the EU-funded BioCog project, registered as NCT02265263, and approved by the local ethics committee with written informed consent from all participants. As populations age and surgical volumes rise, the pressure to predict, and prevent, postoperative delirium and death will only intensify. This study tempers the enthusiasm for one tempting candidate while modeling the discipline required to find predictors that genuinely work.

Subject of Research: Preoperative serum sodium abnormalities and their association with and predictive value for adverse postoperative outcomes in older surgical patients

Article Title: Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort

Article References: Fislage, M., Feinkohl, I., Lammers-Lietz, F., Pischon, T., Winterer, G., Spies, C. D., Borchers, F., Zacharias, N., the BioCog Consortium, Wolf, A., Müller, A., Hadzidiakos, D., Yürek, F., Lachmann, G., Ofosu, K., Heinrich, M., Mörgeli, R., Gallinat, J., Kühn, S., … Fillmer, A. (2026). Preoperative sodium abnormalities and adverse postoperative outcomes in older surgical patients: association and incremental predictive value in the BioCog cohort. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01610-y

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01610-y

Keywords: preoperative sodium, hyponatremia, hypernatremia, postoperative delirium, postoperative complications, mortality, older surgical patients, BioCog cohort, risk prediction, perioperative medicine, geriatric surgery, electrolyte disorders

The study, conducted at Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, focused on complement component C1q, the molecule that fires the opening shot of the classical complement cascade. C1q is an elaborate glycoprotein built from 18 polypeptide chains, with a collagen-like tail that orchestrates immune signaling and a globular head that recognizes a wide range of molecular targets on pathogens, damaged cells, and debris. Long known for its role in tagging microbes and cellular wreckage for destruction, C1q has increasingly been implicated in chronic inflammatory disease, vascular injury, and, intriguingly, in the brain itself. In the central nervous system, C1q helps prune synapses during development, but when reactivated in adulthood, it can drive microglial cells to eliminate synapses that are still needed, a mechanism linked to cognitive decline in several conditions.

The researchers drew on a prospective observational study of neurological complications after type A aortic dissection surgery, registered with the Chinese Clinical Trial Registry. Between January and December 2022, 265 patients scheduled for emergency aortic surgery were screened, and 67 met the strict inclusion criteria: adults with confirmed acute type A dissection undergoing open thoracotomy, free of prior neurological or psychiatric disease, severe cerebral infarction, pregnancy, malignancy, or terminal illness. Blood samples were collected at three time points: immediately upon admission before surgery, on the first morning after the operation, and, for patients who developed delirium, on the morning after they were assessed as awake. Serum C1q concentrations were quantified with a human C1q-specific enzyme-linked immunosorbent assay, while delirium was diagnosed using the Confusion Assessment Method and its ICU variant, administered twice daily for the first three postoperative days and then daily for four more days by trained investigators.

The results were striking. Roughly 55 percent of the enrolled patients developed postoperative delirium, a rate consistent with previous reports for this operation. Those who did had markedly higher serum C1q before surgery: a median of 12.72 nanograms per milliliter, compared with 9.31 nanograms per milliliter in patients who remained clear-headed. The difference persisted after surgery and even after delirious patients regained full awareness, suggesting that elevated C1q is not simply a fleeting response to the trauma of the operation. In univariate logistic analysis, both preoperative and postoperative C1q levels significantly predicted delirium, with preoperative values showing the stronger performance. When the team built a multivariable model refined with LASSO regression and cross-validation, preoperative C1q remained an independent predictor alongside the type of cerebral perfusion used during surgery, with patients receiving retrograde cerebral perfusion facing substantially higher odds of delirium.

The predictive power of the biomarker was quantified with receiver operating characteristic analysis. Preoperative serum C1q achieved an area under the curve of 0.788, with a sensitivity of 65.4 percent and a specificity of 78.4 percent, a level of discrimination that compares favorably with existing candidates such as neuron-specific enolase and S100β, both of which have shown limitations in this clinical setting. Perhaps most compelling was the dose-response relationship. When patients were divided into quartiles by preoperative C1q concentration, the risk of delirium climbed steeply across the gradient: compared with the lowest quartile, the adjusted odds of delirium were 6.72-fold higher in the third quartile and 21.02-fold higher in the fourth, with a statistically significant trend across quartiles. This graded relationship strengthens the case that C1q is not merely correlated with delirium by chance but tracks a genuine biological gradient of susceptibility.

Why would a complement protein measured in the blood, before any surgical insult, foreshadow a delirium that emerges days later? The authors propose that C1q reflects a pre-existing state of immune-inflammatory activation that primes the brain for injury. Delirium is thought to arise when systemic inflammatory mediators cross the blood-brain barrier and activate microglia, the resident immune cells of the brain, triggering neuroinflammation that disrupts synaptic function. Notably, in this study, preoperative C-reactive protein showed only a trend toward elevation in the delirium group without reaching statistical significance, hinting that the relevant process may be neuroinflammatory rather than a blunt systemic inflammatory response. C1q, with its established role in tagging synapses for microglial elimination, fits this picture neatly. In sepsis-associated encephalopathy, recent work has shown that microglia mediate cognitive deficits by engulfing C1q-tagged synapses, and that pharmacologically reducing C1q levels with the oral blocker PLX5622 can prevent neuronal damage and improve neurocognitive outcomes.

C1q also has documented effects on the vasculature that may be relevant to aortic dissection patients specifically. The protein induces proliferation of vascular smooth muscle cells, and elevated circulating levels have been identified as a risk factor for atherosclerosis and arteriolar vasculopathy. In the context of dissection surgery, where cerebral perfusion is deliberately interrupted and restored, and where deep hypothermic circulatory arrest imposes ischemia-reperfusion stress on the brain, a vasculature already primed by complement-driven remodeling may be less resilient. The study found that delirium patients spent longer on mechanical ventilation, stayed in the intensive care unit substantially longer, and suffered pulmonary infections far more often than their non-delirious counterparts, underscoring the clinical weight of this complication even when it appears transient.

The findings do not stand alone. The same group recently reported that serum NPTX2, a marker of synaptic plasticity and neuronal integrity, also predicts postoperative delirium in acute type A dissection patients, with an area under the curve of 0.895 for postoperative measurements. The two biomarkers appear to capture complementary dimensions of the disease: NPTX2 reflects the vulnerability of neurons and synapses, while C1q signals activation of the immune-inflammatory cascade that can exploit that vulnerability. Together, they sketch a two-hit model in which a brain with weakened synaptic reserves meets an immune system primed for complement-mediated attack. The authors suggest that integrating both measurements into preoperative assessment could enable multidimensional risk stratification, allowing clinicians to identify high-risk patients before surgery and to intensify postoperative surveillance, for example by administering cognitive assessments multiple times daily in the ICU.

The research carries clear caveats. The cohort of 67 patients is small, and the authors acknowledge that the findings may not generalize to broader populations. The original study’s blood collection protocol excluded many patients whose samples were inaccessible or hemolyzed, raising the possibility of selection bias, and ethical constraints prevented the comparison of serum C1q with cerebrospinal fluid levels, leaving the link between blood measurements and brain biology indirect. Height, which appeared significant in univariate analysis, was excluded from the final model as biologically implausible and likely a proxy for frailty or nutritional reserve. Even so, the study is the first to demonstrate that preoperative C1q is elevated in patients who go on to develop delirium after aortic dissection, establishing complement pathway activation as a candidate susceptibility marker rather than a mere acute-phase echo of surgical stress. If larger trials confirm the result, complement profiling could become a routine part of preoperative evaluation for one of cardiac surgery’s most feared complications, and drugs that temper the complement cascade, already in development for other conditions, could open a genuine therapeutic frontier for protecting the surgical brain.

Subject of Research: Serum complement C1q as a predictive biomarker for postoperative delirium after acute type A aortic dissection surgery

Article Title: Serum C1q as a Novel Predictive Biomarker for Postoperative Delirium After Acute Type A Aortic Dissection

Article References: Serum C1q as a Novel Predictive Biomarker for Postoperative Delirium After Acute Type A Aortic Dissection. (n.d.). https://doi.org/10.1002/iid3.70500

Image Credits: AI Generated

DOI: 10.1002/iid3.70500

Keywords: C1q, complement system, postoperative delirium, aortic dissection, biomarker, neuroinflammation, cardiac surgery, microglia, NPTX2, risk prediction, cerebral perfusion, ICU